giredestrant
roche
['acelera', 'mbc', 'giredestrant', 'medsir']
primary results of acelera bc comparing giredestrant vs endocrine monotherapy physician s choice for er+, her2 la/mbc in the 2nd/3rd line did not meet primary endpoint of pfs (hr 0.81). cbr (32% vs 21%) and orr (13% vs 7%) were higher in giredestrant group. dr. jimenez #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM